PHARMACY

PhRMA shows record number of heart disease, stroke meds in the pipeline

BY Alaric DeArment

WASHINGTON A new report from the Pharmaceutical Research and Manufacturers of America shows a record number of heart disease and stroke medications in the development pipeline, PhRMA said Thursday.

More than 300 new medicines for treating two of the top killers in the country are in clinical trials or awaiting approval by the Food and Drug Administration, compared to 146 in 2005.

“The medicines now in the research pipeline will add to the substantial progress made by America’s pharmaceutical research and biotechnology companies in developing new and more effective treatments for these diseases,” PhRMA president and CEO Billy Tauzin stated. “This strong commitment to research is a product of the determination of the researchers and scientists working to develop new medicines that enable patients to live longer, healthier and more productive lives.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Take Care Health Systems opens New Orleans clinic

BY Antoinette Alexander

CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened a new clinic in the New Orleans area.

The new location makes four Take Care Clinics in that market. In total, the clinic operator has 332 clinics in 35 markets throughout 19 states. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eli Lilly’s chemotherapy drug granted tentative approval by FDA

BY Alaric DeArment

ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to a generic version of Eli Lilly & Co.’s chemotherapy drug Gemzar, agency records show.

The FDA issued the tentative approval Monday to Hospira’s 2 g gemcitabine hydrochloride injection. The drug is used to treat non-small cell lung cancer, pancreatic cancer, ovarian, breast cancer and others. 

Gemzar had worldwide sales of $1.6 billion in 2007, according to Lilly financial data. According to the FDA Orange Book, the drug will lose patent protection next year. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?